Maryland legislation · 2026 Regular Session
Maryland SB435: Public Health - Medetomidine and Xylazine Consumer Protection Act
Status: In committee, April 13, 2026
Prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or xylazine product unless the purchaser provides proof the intended use is for institutional, veterinary, or scientific purposes; prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine or xylazine product to an individual under the age of 21 years; requiring a retailer that prepares, distributes, sells, or exposes for sale a medetomidine or xylazine product to maintain certain records; etc.
What the bill says
From the chaptered text, April 10, 2026:
SB0435/983727/1 BY: Finance Committee AMENDMENTS TO SENATE BILL 435 (First Reading File Bill) AMENDMENT NO. 1 On page 1, in line 2, strike "Public Health" and substitute "Criminal Law - Schedule III Controlled Dangerous Substances"; in the same line, strike "Consumer Protection Act"; strike beginning with "prohibiting" in line 3 down through "Fund" in line 11 and substitute "establishing medetomidine and xylazine as Schedule III controlled dangerous substances under the Maryland Controlled Dangerous Substances Act"; in line 12, strike "products"; and strike in their entirety lines 13 through 28, inclusive, and substitute: "BY repealing and reenacting, with amendments, Article - Criminal Law Section 5-404 Annotated Code of Maryland (2021 Replacement Volume and 2025 Supplement)". AMENDMENT NO. 2 On pages 2 through 4, strike in their entirety the lines beginning with line 3 on page 2 through line 2 on page 4, inclusive, and substitute: "Article - Criminal Law 5-404. (a) Schedule III consists SB0435/983727/01 Finance Committee Amendments to SB 435 (2) XYLAZINE; AND (3) each controlled dangerous substance by whatever official name, common or usual name, chemical name, or brand name: [(1)] (I) added to Schedule III by the Department under § 5-202(b) of this title; or [(2)] (II) designated as a Schedule III controlled dangerous substance by the federal government unless the Department objects under § 5-202(f) of this …
Sponsors
- William Folden (R, 4) · primary sponsor
Latest actions
- : Motion Laid Over (Senator Ready) Adopted
- : Favorable with Amendments {983727/1
- : Favorable with Amendments Report by Finance
- : Hearing 2/11 at 2:00 p.m.
- : First Reading Finance
Common questions
- What is SB435?
- SB435 is a bill in the Maryland Legislature (2026 Regular Session): Public Health - Medetomidine and Xylazine Consumer Protection Act.
- What does SB435 do?
- Prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or xylazine product unless the purchaser provides proof the intended use is for institutional, veterinary, or scientific purposes; prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine or xylazine product to an individual under the age of 21 years; requiring a retailer that prepares, distributes, sells, or exposes for sale a medetomidine or xylazine product to maintain certain records; etc.
- What is the status of SB435?
- In committee as of April 13, 2026. Latest action: Motion Laid Over (Senator Ready) Adopted (April 13, 2026).
- Who sponsored SB435?
- William Folden (R, 4).
- Where is the official record for SB435?
- On the Maryland Legislature website: https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/sb0435?ys=2026RS
Source: official Maryland record. Tracked by Delilah, AI for legislation across all 50 states and Congress.